DEA Wants Way More Cannabis & Psychedelics for Research In 2022

The DEA has proposed massively increasing the production of research-grade cannabis and psychedelics like LSD, psilocybin, and MDMA next year.

Full story after the jump.

The Drug Enforcement Administration (DEA) is calling for massively increasing the production of research-grade cannabis and psychedelics for 2022, Marijuana Moment reports. The federal agency announced the change in a notice posted to the Federal Register this morning.

Two months ago, DEA already proposed a dramatic increase in cannabis and psychedelics production for 2021.

“There has been a significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes. … DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021.” — Excerpt from DEA’s Federal Register notice

Under the proposal for increased production, DEA is calling for 3,200 grams of MDMA (an increase of 6,300%), doubling the production of psilocybin to 3,000 grams, and doubling cannabis extract production to 1,000,000 grams. The cannabis flower production quota saw a proposed increase of 1,200,000 grams for a grand total of 3,200,000 grams.

The notice includes a call for public input regarding the proposed production increases.

Currently, the licensed production of research-grade cannabis is limited to the University of Mississippi but DEA called for applications for additional cultivators and other producers of Schedule I substances. Those licenses have been long-awaited and many activists and interested parties have accused the agency of foot-dragging on the issue, but DEA said earlier this year it was poised to issue several of the licenses.

“[DEA] is working diligently to review and approve applications for schedule I manufacturers of marihuana (sic.) that conform to the federal requirements contained in the CSA,” the agency said in today’s notice.

Get daily cannabis business news updates. Subscribe

Have an additional perspective to share? Send us a message to let us know, and if your comment is chosen by our editors it could be featured here.

Sponsor message:

End


Latest Cannabis News

View all news Get email updates

Create a profile View all categories

From Our Partners